Latest Prescription Drug User Fee Act Stories
The First, Once-Daily, Extended-Release Amphetamine-based Oral Liquid for the Treatment of ADHD MONMOUTH JUNCTION, N.J., May 21, 2015 /PRNewswire/ -- Tris Pharma, Inc.
LEXINGTON, Mass., Feb.
TARRYTOWN, N.Y. and PARIS, Jan. 26, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S.
ALISO VIEJO, Calif., Nov. 7, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S.
QUÉBEC CITY, Oct. 27, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced the formal implementation of its own full-time U.S.
HAYWARD, Calif., Sept. 17, 2014 /PRNewswire/ -- Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the U.S.
MONMOUTH JUNCTION, N.J., Sept. 15, 2014 /PRNewswire/ -- Vernalis plc (LSE: VER) and Tris Pharma, Inc. ("Tris") are pleased to announce that the U.S.
-- Company Expects to File IND to Support Clinical Trials in Mid-2015 -- ROCKVILLE, Md., Sept.
The Emergence of Keytruda--the First PD-1 Inhibitor Approved in the U.S.--is a Significant Milestone in Oncology, According to Decision Resources Group BURLINGTON, Mass., Sept.
NORTHBROOK, Ill., Sept. 6, 2014 /PRNewswire/ -- Astellas today announced that the U.S.
- The analysis of literature, focusing on the words and grammar to the exclusion of context or literary merit.